MedImmune’s FluMist proves superior to injectable vaccine in trial

Share this article:
MedImmune said yesterday that a new version of its FluMist nasal-spray influenza vaccine had proved superior for young children to the standard flu shot in a large global test.
The findings could potentially give a much-needed boost to sales of what has become a flagging product for MedImmune.
In a test of 8,492 children in 26 countries, only 3.9% of children receiving FluMist got the flu, versus 8.6% of those who received standard flu shots, a 55% drop, MedImmune said.
The study is the third and largest study of FluMist. The new product still awaits approval from the FDA, which has refrained from allowing its use in children.
"The injectable vaccine has been in use for more than 40 years," MedImmune CEO David Mott told The Washington Post, in an interview. "We have just demonstrated that we have the potential to demonstrate 55% better efficacy at preventing influenza. That's a pretty important finding."
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies